MolGraph
CompoundsDocumentationComplianceAbout
MolGraph

Research chemical sourcing and molecular building block RFQ workflows.

MolGraph is operated by Tessorix Inc.

support@molgraph.com

Products are intended for laboratory research use only and are not for human or veterinary use.

Compounds

  • Compound catalog
  • CAS Search

Company

  • About
  • Contact

Documentation

  • Quality Documentation
  • SDS Disclaimer

Compliance

  • Compliance

Legal

  • Terms
  • Privacy

Copyright © 2026 MolGraph. All Rights Reserved.

Home/Compounds/CAS 112811-59-3
Formula C19H22FN3O4MW 375.4Research-use catalog entryCOA/SDS by request

Gatifloxacin

CAS Number: 112811-59-3

Sourcing & RFQ

Submit an RFQ to review pricing, availability, lead time, pack size, purity, COA, and supplier SDS for this catalog entry.

Available options

Available Options

Package
1 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
10 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
100 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
25 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
5 g
Purity
98%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required

Shipping review is required before pricing or stock can be confirmed publicly. Shipping, duties, and documentation fees are confirmed before order acceptance.

Loading RDKit molecule structure...
InChIKey: XUBOMFCQGDBHNK-UHFFFAOYSA-NC19H22FN3O4 | MW 375.4

Chemical Absolute Identifiers

CAS Number

112811-59-3

PubChem CID

5379

Molecular Formula

C19H22FN3O4

Molecular Weight

375.4 g/mol

Exact Mass

375.159434

InChIKey

XUBOMFCQGDBHNK-UHFFFAOYSA-N

IUPAC Name

1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

SMILES String

CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F

Physical Properties

Melting Point

182–185 °C

Properties are provided as catalog reference data and may be confirmed through supplier documentation when required.

Catalog Facts

Structural features

Gatifloxacin (CAS 112811-59-3) is listed in the Pharmaceutical Intermediates portfolio, with molecular formula C19H22FN3O4 and molecular weight 375. 40 g/mol.

Sourcing context

Catalog reference for RFQ preparation, supplier confirmation, and research chemical sourcing review.

Research use context

Intended for research-stage medicinal chemistry and intermediate synthesis workflows; structure-derived tags include nitrogen-containing heterocycle.

Documentation needs

COA/SDS status, availability, lead time, pack size, and shipment documentation can be confirmed during quotation.

Applications & Classification

Pharmaceutical Intermediate ResearchResearch intermediateCustom synthesis building blockPharmaceutical intermediate researchResearch chemical sourcingCustom synthesis and catalog availability reviewCOA, SDS, pricing, and fulfillment workflow
Biological target reference

ChEMBL reports experimental activity evidence for: DNA gyrase (Escherichia coli) — 2 assays; DNA gyrase subunit A (Mycobacterium tuberculosis) — 3 assays; Tyrosyl-DNA phosphodiesterase 1 (Homo sapiens) — 4 assays; Mu-type opioid receptor (Homo sapiens) — 2 assays; 5-hydroxytryptamine receptor 1A (Homo sapiens) — 2 assays. These records describe research assays and do not establish therapeutic efficacy or clinical use.

DNA gyrase

Escherichia coli · PROTEIN COMPLEX · 2 qualifying assays · 2 documents · best pChEMBL 6.3

Experimental evidence source: ChEMBL

DNA gyrase subunit A

Mycobacterium tuberculosis · SINGLE PROTEIN · 3 qualifying assays · 1 documents · best pChEMBL 5.03

Experimental evidence source: ChEMBL

Tyrosyl-DNA phosphodiesterase 1

Homo sapiens · SINGLE PROTEIN · 4 qualifying assays · 1 documents · best pChEMBL 4.55

Experimental evidence source: ChEMBL

Mu-type opioid receptor

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents · best pChEMBL 4.55

Experimental evidence source: ChEMBL

5-hydroxytryptamine receptor 1A

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Safety & Handling

Handling & Storage

  • Keep container tightly closed and dry.
  • Store in a well-ventilated place.

PPE

Respiratory protection if needed

First Aid

  • Do not give anything to an unconscious person.
  • Rinse mouth with water.

Stability / Reactivity

  • Reactivity and reaction stability.
  • Carbon monoxide, carbon dioxide, hydrogen fluoride, nitrogen oxides.

Disposal

  • Waste product: Dispose of remaining and non-recyclable solutions to a licensed company.
  • Contact a professional organization with a waste disposal license to handle this substance.
Show additional safety reference fields

Fire Fighting

  • If necessary, wear a self-contained breathing apparatus for firefighting.

Accidental Release

  • Do not generate dust when collecting and disposing.
  • Sweep and shovel up.

For supplier-issued SDS, request documentation before handling, storage, shipment, or procurement decisions.

Preliminary Safety Reference

For supplier-issued SDS or COA, submit a documentation request.

Safety Reference / SDS Request

Names & Synonyms / External Identifiers

Chemical Name

Gatifloxacin

Names & Synonyms

TequinGatifloZymarGatifloxacineZymaxid
Show all synonyms
Zymergatifloxacin anhydrousAM 11553-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-gatifloxacino1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acidgatifloxacinumGatifloxacin (sesquihydrate)(+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acidBMS 2065841-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-4-ium-1-yl)-4-oxoquinoline-3-carboxylate1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
External Identifiers
EC NUMBER: 664-293-2DSSTOX SUBSTANCE ID: DTXSID5045704CHEMBL ID: CHEMBL31CHEBI ID: CHEBI:5280UNII: 81485Y3A9ADRUGBANK ID: DB01044HMDB ID: HMDB0015178KEGG ID: C07661KEGG ID: D08011METABOLOMICS WORKBENCH ID: 144329NCI THESAURUS CODE: C175722NCI THESAURUS CODE: C29070PHARMGKB ID: PA449738RXCUI: 1546025RXCUI: 228476
Experimental Spectrum References
13C NMR SpectraATR-IR Spectra — Forensic Spectral ResearchFTIR Spectra — Forensic Spectral ResearchRaman Spectra — Forensic Spectral Research
Literature & Patent References
DOI 10.1016/j.ejmech.2023.116056Plasmodium falciparum topoisomerases: Emerging targets for anti-malarial therapy.DOI 10.1016/j.ejmech.2024.116785Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment.DOI 10.1016/j.isci.2024.108907Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelDOI 10.1021/acs.jmedchem.4c01733Comprehensive Insights into the Development of Antitoxoplasmosis Drugs: Current Advances, Obstacles, and Future Perspectives.PMID 38171145Plasmodium falciparum topoisomerases: Emerging targets for anti-malarial therapy.PMID 38318365Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelPMID 39191032Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment.PMID 39589152Comprehensive Insights into the Development of Antitoxoplasmosis Drugs: Current Advances, Obstacles, and Future Perspectives.

Documentation & Compliance Facts

Compliance Facts

Shipment review: Required

Documentation available by request

Certificate of Analysis (COA): By request

Supplier Safety Data Sheet (SDS): By request

Purity and pack size confirmation: By request

Availability and lead time review: Confirmed by RFQ

Shipment documentation review: By request

For supplier-issued documentation by request, use the RFQ actions on this page.Review preliminary safety reference

What happens after RFQ

  1. 1We review the CAS identity, quantity, and documentation request.
  2. 2We check sourcing options, supplier availability, COA/SDS, purity, pack size, and lead time.
  3. 3We review destination and shipment documentation needs when applicable.
  4. 4We follow up with a quotation or clarification request.

Text Reference Cues

Show non-linked catalog cues

Non-public related references

Gatifloxacin hydrochlorideCAS 121577-32-0
Gatifloxacin sesquihydrateCAS 180200-66-2
Besifloxacin HydrochlorideCAS 405165-61-9
OrbifloxacinCAS 113617-63-3
NadifloxacinCAS 124858-35-1

Non-public references are shown as text only and do not imply equivalence, availability, or shared use.

Catalog navigation

Related Catalog Entries

Other public CAS pages in this catalog. These links support navigation across additional intermediates and do not imply equivalence, availability, or shared use.

CAS 121577-32-0Gatifloxacin hydrochlorideCAS 180200-66-2Gatifloxacin sesquihydrateCAS 405165-61-9Besifloxacin HydrochlorideCAS 113617-63-3OrbifloxacinCAS 124858-35-1NadifloxacinCAS 100643-71-8DesloratadineCAS 123318-82-1ClofarabineCAS 104227-87-4FamciclovirCAS 1156-19-0TolazamideCAS 1002310-00-0Tert-butyl 1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylcarbamate

RFQ questions for CAS 112811-59-3

What are the key identifiers for Gatifloxacin (CAS 112811-59-3)?

Gatifloxacin is identified by CAS 112811-59-3, with molecular formula C19H22FN3O4, molecular weight 375.4, InChIKey XUBOMFCQGDBHNK-UHFFFAOYSA-N.

Does CAS 112811-59-3 have reported biological target evidence?

ChEMBL contains qualifying experimental assay evidence associated with DNA gyrase, DNA gyrase subunit A, Tyrosyl-DNA phosphodiesterase 1, Mu-type opioid receptor, 5-hydroxytryptamine receptor 1A. These records do not establish therapeutic efficacy or clinical use.

Can I request a COA for CAS 112811-59-3?

Yes. Submit an RFQ and specify COA requirements. Lot-specific COA depends on supplier confirmation.

Can I request supplier SDS for Gatifloxacin?

Yes. Supplier SDS can be requested through the RFQ workflow before handling, storage, shipment, or procurement decisions.

Is CAS 112811-59-3 available for quotation?

Availability, pack size, lead time, and pricing are confirmed through RFQ.

Can MolGraph support bulk sourcing or custom synthesis review?

Submit the CAS number, quantity, purity requirement, and destination country for sourcing review.